Search

Your search keyword '"Manzione, L"' showing total 312 results
Start Over Author "Manzione, L"
312 results on '"Manzione, L"'

8. Lapatinib in breast cancer

Author

Bilancia, D., Rosati, G., Dinota, A., Germano, D., Romano, R., and Manzione, L.

Published
2007

28. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)

Author

DE VITA, Ferdinando, GIULIANI F, ORDITURA, Michele, MAIELLO E, GALIZIA, Gennaro, DI MARTINO, Natale, MONTEMURRO F, CARTEN G, MANZIONE L, ROMITO S, GEBBIA V, CIARDIELLO, Fortunato, CATALANO, G, COLUCCI G, GRUPPO ONCOLOGICO ITALIA MERIDIONALE, DE VITA F, GIULIANI F, ORDITURA M, MAIELLO E, GALIZIA G, DI MARTINO N, MONTEMURRO F, CARTENI G, MANZIONE L, ROMITO S, GEBBIA V, CIARDIELLO F, CATALANO G, COLUCCI G, GRUPPO ONCOLOGICO ITALIA MERIDIONALE, DE VITA, Ferdinando, Giuliani, F, Orditura, Michele, Maiello, E, Galizia, Gennaro, DI MARTINO, Natale, Montemurro, F, Carten, G, Manzione, L, Romito, S, Gebbia, V, Ciardiello, Fortunato, Catalano, G, Colucci, G, and GRUPPO ONCOLOGICO ITALIA, Meridionale

Subjects
Adjuvant chemotherapy
Abstract

Adjuvant chemotherapy

Published
2007

29. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study

Author

Maione, P, Perrone, F, Gallo, C, Manzione, L, Piantedosi, F, Barbera, S, Cigolari, S, Rosetti, F, Piazza, E, Robbiati, Sf, Bertetto, O, Novello, S, Migliorino, Mr, Favaretto, A, Spatafora, M, Ferraù, F, Frontini, L, Bearz, A, Repetto, L, Gridelli, C, Barletta, E, Barzelloni, Ml, Iaffaioli, Rv, DE MAIO, E, DI MAIO, M, DE FEO, G, Sigoriello, G, Chiodini, P, Cioffi, A, Guardasole, V, Angelini, V, Rossi, A, Bilancia, D, Germano, D, Lamberti, A, Pontillo, V, Brancaccio, L, Renda, F, Romano, F, Esani, G, Gambaro, A, Vinante, O, Azzarello, G, Clerici, M, Bollina, R, Belloni, P, Sannicolò, M, Ciuffreda, L, Parello, G, Cabiddu, M, Sacco, C, Sibau, A, Porcile, G, Castiglione, F, Ostellino, O, Monfardini, S, Stefani, M, Scagliotti, G, Selvaggi, G, DE MARINIS, F, Martelli, O, Gasparini, G, Morabito, A, Gattuso, D, Colucci, G, Galetta, D, Giotta, F, Gebbia, V, Borsellino, N, Testa, A, Malaponte, E, Capuano, Ma, Angiolillo, M, Sollitto, F, Tirelli, U, Spazzapan, S, Adamo, V, Altavilla, G, Scimone, A, Hopps, Mr, Tartamella, F, Ianniello, Gp, Tinessa, V, Failla, G, Bordonaro, R, Gebbia, N, Valerio, Mr, D'Aprile, M, Veltri, E, Tonato, M, Darwish, S, Romito, S, Carrozza, F, Barni, S, Ardizzoia, A, Corradini, Gm, Pavia, G, Belli, M, Colantuoni, G, Galligioni, E, Caffo, O, Labianca, R, Quadri, A, Cortesi, Enrico, D'Auria, Giuliana, Fava, S, Calcagno, A, Luporini, G, Locatelli, Mc, DI COSTANZO, F, Gasperoni, S, Isa, L, Candido, P, Gaion, F, Palazzolo, G, Nettis, G, Annamaria, A, Rinaldi, M, Lopez, M, Felletti, R, DI NEGRO GB, Rossi, N, Calandriello, A, Maiorino, L, Mattioli, R, Celano, A, Schiavon, S, Illiano, A, Raucci, Ca, Caruso, M, Foa, P, Tonini, G, Curcio, C, Cazzaniga, M., MAIONE P, PERRONE F, GALLO C, MANZIONE L, PIANTEDOSI F, BARBERA S, CIGOLARI, ROSETTI F, PIAZZA E, ROBBIATI SF, BERTETTO O, NOVELLO S, MIGLIORINO MR, FAVARETTO A, SPATAFORA M, FERRAU F, FRONTINI L, BEARZ A, REPETTO L, GRIDELLI C, BARLETTA E, BARZELLONI ML, IAFFAIOLI RV, DE MAIO E, DI MAIO M, DE FEO G, SIGORIELLO G, CHIODINI P, CIOFFI A, GUARDASOLE V, ANGELINI V, ROSSI A, BILANCIA, GERMANO D, LAMBERTI A, PONTILLO V, BRANCACCIO L, RENDA F, ROMANO F, ESANI G, GAMBARO A, VINANTE O, AZZARELLO G, CLERICI M, BOLLINA R, BELLONI P, SANNICOLO M, CIUFFREDA L, PARELLO G, CABIDDU M, SACCO C, SIBAU A, PORCILE G, CASTIGLIONE F, OSTELLINO O, MONFARDINI S, STEFANI M, SCAGLIOTTI G, SELVAGGI G, DE MARINIS F, MARTELLI O, GASPARINI G, MORABITO A, GATTUSO D, COLUCCI G, GALETTA D, GIOTTA F, GEBBIA V, ET AL, Maione, P, Perrone, F, Gallo, Ciro, Manzione, L, Piantedosi, F, Barbera, S, Cigolari, S, Rosetti, F, Piazza, E, Robbiati, Sf, Bertetto, O, Novello, S, Migliorino, Mr, Favaretto, A, Spatafora, M, Ferrau, F, Frontini, L, Bearz, A, Repetto, L, and Gridelli, C.

Subjects
Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Activities of daily living, Health Status, carcinoma, Vinblastine, Vinorelbine, Deoxycytidine, older people, Quality of life, Instrumental activitie, Carcinoma, Non-Small-Cell Lung, Internal medicine, Activities of Daily Living, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Lung cancer, Aged, Aged, 80 and over, validation, Proportional hazards model, business.industry, QLQ-C30, Age Factors, Cancer, clinical trial, Prognosis, medicine.disease, Gemcitabine, Comorbidity, humanities, comorbidity, Oncology, Quartile, Quality of Life, Physical therapy, impact, Geriatric oncology, Female, business, Randomized-trial, medicine.drug
Abstract

Purpose To study the prognostic value for overall survival of baseline assessment of functional status, comorbidity, and quality of life (QoL) in elderly patients with advanced non—small-cell lung cancer treated with chemotherapy. Patients and Methods Data from 566 patients enrolled onto the phase III randomized Multicenter Italian Lung Cancer in the Elderly Study (MILES) study were analyzed. Functional status was measured as activities of daily living (ADL) and instrumental ADL (IADL). The presence of comorbidity was assessed with a checklist of 33 items; items 29 and 30 of the European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 (EORTC QLQ-C30) were used to estimate QoL. ADL was dichotomized as none versus one or more dependency. For IADL and QoL, three categories were defined using first and third quartiles as cut points. Comorbidity was summarized using the Charlson scale. Analysis was performed by Cox model, and stratified by treatment arm. Results Better values of baseline QoL (P = .0003) and IADL (P = .04) were significantly associated with better prognosis, whereas ADL (P = .44) and Charlson score (P = .66) had no prognostic value. Performance status 2 (P = .006) and a higher number of metastatic sites (P = .02) also predicted shorter overall survival. Conclusions Pretreatment global QoL and IADL scores, but not ADL and comorbidity, have significant prognostic value for survival of elderly patients with advanced non—small-cell lung cancer who were treated with chemotherapy. Using these scores in clinical practice might improve prognostic prediction for treatment planning.

Published
2005

30. Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide

Author

Papaldo, P., Lopez, M., Cortesi, Enrico, Cammilluzzi, E., Antimi, M., Terzoli, E., Lepidini, G., Vici, P., Barone, C., Ferretti, G., Di Cosimo, S., Nistico, C., Carlini, P., Conti, F., Di Lauro, L., Botti, C., Vitucci, C., Fabi, A., Giannarelli, D., Marolla, P., Di Maio, M., Perrone, F., Gallo, C., Iaffaioli, R. V., Manzione, L., Piantedosi, F. V., Cigolari, S., Illiano, A., Barbera, S., Robbiati, S. F., Piazza, E., Ianniello, G. P., Frontini, L., Veltri, E., Castiglione, F., Rosetti, F., De Maio, E., Maione, P., Gridelli, C., Rossi, A., Barletta, E., Barzelloni, M. L., Signoriello, G., Bilancia, D., Dinota, A., Rosati, G., Germano, D., Lamberti, A., Pontillo, V., Brancacio, L., Crispino, C., Esposito, M., Battiloro, C., Tufano, G., Cioffi, A., Guardasole, V., Angelini, V., Guidetti, G., Renda, F., Romano, F., Volpintesta, A., Sannicolo, M., Filipazzi, V., Esani, G., Gambaro, A., Ferrario, S., Tinessa, V., Caprio, M. G., Zonato, S., Cabiddu, M., Raina, A., D'Aprile, M., Pistillucci, G., Porcile, G., Ostellino, O., Vinante, O., Azzarello, G., Gebbia, V., Borsellino, N., Testa, A., Gasparini, G., Morabito, A., Gattuso, D., Romito, S., Carrozza, F., Fava, S., Calcagno, A., Grimi, E., Bertetto, O., Ciuffreda, L., Parello, G., Maiorino, L., Santoro, A., Santoro, M., Failla, G., Aiello, R. A., Bearz, A., Sorio, R., Scalone, S., Clerici, M., Bollina, R., Belloni, P., Sacco, C., Sibau, A., Adamo, V., Altavilla, G., Scimone, A., Spatafora, M., Bellia, V., Hopps, M. R., Monfardini, S., Favaretto, A., Stefani, M., Corradini, G. M., Pavia, G., Scagliotti, G., Novello, S., Selvaggi, G., Tonato, M., Darwish, S., Michetti, G., Belometti, M. O., Labianca, R., Quadri, A., De Marinis, F., Migliorino, M. R., Martelli, O., Colucci, G., Galetta, D., Giotta, F., Isa, L., Candido, P., Rossi, N., Calandriello, A., Ferrau, F., Malaponte, E., Barni, S., Cazzaniga, M., Gebbia, N., Valerio, Mr, Belli, M., Colantuoni, G., Capuano, M. A., Angiolillo, M., Sollitto, F., Ardizzoia, A., Luporini, G., Locatelli, M. C., Pari, F., Aitini, E., Pedicini, T., Febbraro, A., Zollo, C., Di Costanzo, F., Bartolucci, R., Gasperoni, S., Gaion, F., Palazzolo, G., Galligioni, E., Caffo, O., Cortesi, E., D'Auria, G., Curcio, C., Vasta, M., Bumma, C., Celano, A., Bretti, S., Nettis, G., Anselmo, A., Mattioli, R., Aschelter, A., and Foa, P.

Subjects
Adult, Cancer Research, medicine.medical_specialty, Indazoles, Filgrastim, Cyclophosphamide, medicine.medical_treatment, Breast Neoplasms, Gastroenterology, Disease-Free Survival, chemistry.chemical_compound, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Granulocyte Colony-Stimulating Factor, medicine, Humans, Survival rate, Aged, Epirubicin, Chemotherapy, business.industry, Lonidamine, Middle Aged, medicine.disease, Metastatic breast cancer, Recombinant Proteins, Granulocyte colony-stimulating factor, Surgery, Survival Rate, Oncology, chemistry, Female, business, Follow-Up Studies, medicine.drug
Abstract

Purpose: Lonidamine (LND) can enhance the activity of anthracyclines in patients with metastatic breast cancer. A multicenter, prospective, randomized trial was designed to determine whether the association of LND with high-dose epirubicin plus cyclophosphamide (EC) could improve disease-free survival (DFS) in patients with early breast cancer (BC) compared with EC alone. Granulocyte colony-stimulating factor (G-CSF) was added to maintain the EC dose-intensity. Patients and Methods: From October 1991 to April 1994, 506 patients with stage I/II BC were randomly assigned to four groups: (A) epirubicin 120 mg/m2 and cyclophosphamide 600 mg/m2 administered intravenously on day 1 every 21 days for four cycles (124 patients); (B) EC plus LND 450 mg/d administered orally (125 patients); (C) EC plus G-CSF administered subcutaneously (129 patients); (D) EC plus LND plus G-CSF (128 patients). Results: Median follow-up was 55 months. Five-year DFS rate was similar for LND (B+D groups; 69.6%) versus non-LND arms (A+C groups; 70.3%) and G-CSF (C+D groups; 67.2%) versus non–G-CSF arms (A+B groups; 72.9%). Five-year overall survival (OS) was comparable in LND (79.1%) versus non-LND arms (81.3%) and in G-CSF (80.6%) versus non–G-CSF arms (79.6%). DFS and OS distributions in LND and G-CSF arms did not change according to tumor size, node, receptor, and menopausal status. G-CSF dramatically reduced hematologic toxicity without having a significant impact on dose-intensity (98.1% v 95.5% for C+D and A+B groups, respectively). Conclusion: EC is active and well tolerated in patients with early breast cancer. The addition of LND or G-CSF does not improve DFS or OS.

Published
2003

31. Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey

Author

MERCADANTE, S, ROILA, F, BERRETTO, O, LABIANCA, R, CASILINI, S, BOTTERO, G, TROVA, V, CASCINU, S, DI VITO, F, LORUSSO, V, TROCCOLI, G, ENDRIZZI, L, DANIELE, B, MARTONI, A, MARINI, G, VITELLO, S, ROMITO, S, SBALZARINI, G, SERRAVEZZA, G, MANENTE, P, MOLICA, S, PALAZZO, S, PRANTERA, T, MERLANO, M, DI GIROLAMO, G, AMADORI, D, SOBRERO, A, ALGERI, R, BRETTI, S, GRECO, E, D'APRILE, M, FORCIGNANO, C, BONETTI, A, AITINI, E, PIAZZA, E, PIVA, L, TABBIADON, D, CARTENI', G, CATALANO, G, ALABISO, O, LANDRISCINA, G, DOGLIOTTI, L, FILIPPELLI, G, BERTE', R, RICCI, S, MANZIONE, L, IACONO, C, MARANGOLO, M., GEBBIA, Nicolo', PALMERI, Sergio, MERCADANTE, S, ROILA, F, BERRETTO, O, LABIANCA, R, CASILINI, S, BOTTERO, G, TROVA, V, CASCINU, S, DI VITO, F, LORUSSO, V, TROCCOLI, G, ENDRIZZI, L, DANIELE, B, MARTONI, A, MARINI, G, VITELLO, S, ROMITO, S, SBALZARINI, G, SERRAVEZZA, G, MANENTE, P, MOLICA, S, PALAZZO, S, PRANTERA, T, MERLANO, M, DI GIROLAMO, G, AMADORI, D, SOBRERO, A, ALGERI, R, BRETTI, S, GRECO, E, D'APRILE, M, FORCIGNANO, C, BONETTI, A, AITINI, E, PIAZZA, E, PIVA, L, TABBIADON, D, CARTENI', G, CATALANO, G, ALABISO, O, LANDRISCINA, G, DOGLIOTTI, L, GEBBIA, N, PALMERI, S, FILIPPELLI, G, BERTE', R, RICCI, S, MANZIONE, L, IACONO, C, and MARANGOLO, M

Subjects
Adult, Male, medicine.medical_specialty, Settore MED/06 - Oncologia Medica, Cross-sectional study, Pain medicine, MEDLINE, Pain, Severity of Illness Index, Neoplasms, Oncology Service, Hospital, Epidemiology, Severity of illness, medicine, Prevalence, Humans, Aged, Aged, 80 and over, Primary Health Care, business.industry, Cancer pain,Epidemiology,Opioids, Nursing research, Physicians, Family, Middle Aged, Large sample, Analgesics, Opioid, Cross-Sectional Studies, Oncology, Italy, Family medicine, Health Care Surveys, Physical therapy, Female, Cancer pain, business
Abstract

The aim of this national cross-sectional survey was to draw information on pain prevalence and intensity from a large sample of patients who were admitted to oncologic centres for different reasons and to evaluate the pain treatment and possible influencing factors.A total of 2,655 patients completed the study. Nine hundred and one patients (34%) reported pain.Higher pain levels were observed in inpatients, in the presence of bone metastases, and with low levels of Eastern Cooperative Oncology Group status. The number of patients receiving strong opioids increased with the highest levels of pain. However, a significant part of patients with moderate-severe pain were not receiving appropriate medication, patients being predominantly administered non-opioid drugs. General practitioners' attitudes did not negatively influence the opioid prescription.The results of this survey indicate a need for continuing educational and informative program in pain management for oncologists and more generally for any physician dealing with cancer patients.

Published
2008

32. Triplets versus doublets with or without cisplatin in the first-line treatment of stage IIIB-IV nonsmall cell lung cancer (NSCLC) patients: Preliminary results of a multicenter randomized factorial study

Author

Tiseo, M., Boni, C., Baldini, E., Luca Boni, Recchia, F., Barone, C., Manzione, L., Grossi, F., Matano, E., Zanelli, F., Prochilo, T., Ardizzoni, A., Tiseo M, Boni C, Baldini E, Boni L, Recchia F, Barone C, Manzione L, Grossi F, Matano E, Zanelli F, Prochilo T, and Ardizzoni A

Subjects
NSCLC
Abstract

Background: The FAST is a 2 × 2 factorial trial addressing two questions: (1) the role of replacing cisplatin (P) with a non-platinum agent, vinorelbine (N), and (2) the role of adding a third agent, ifosfamide (I), in a doublet based on gemcitabine (G). Methods: A total of 433 stage IIIB-IV non-small cell lung cancer (NSCLC) patients were randomised to one of four arms: gemcitabine-cisplatin (GP), gemcitabine-vinorelbine, gemcitabine-ifosfamide-cisplatin or gemcitabine-ifosfamide-vinorelbine. Two comparisons were performed: N- vs P-containing regimens and I-triplets vs non-I doublets. Results: For N- vs P-containing regimens, adjusted overall survival was 9.7 vs 11.3 months (P=0.044), progression-free survival was 4.9 vs 6.4 months (P=0.020) and response rate was 24% vs 31% (P=0.124), respectively. No statistically significant difference was observed between doublets and triplets. Grade 3-4 haematological toxicity was significantly more frequent in P-containing therapy; grade 3-4 leucopenia was significantly more common in triplets. Concerning non-haematological toxicity, grade 3-4 nausea-vomiting was significantly increased in P-containing regimens. Conclusions: This trial provides evidence of a slight survival superiority of GP-containing regimens over platinum-free N-containing chemotherapy. This trial also confirms that the addition of a third chemotherapy agent (I) to a standard G-based doublet does not improve treatment outcome.

Published
2007

35. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer

Author

IAFFAIOLI RV, FORMATO R, TORTORIELLO A, DEL PRETE S, PAPPAGALLO G, PISANO A, GEBBIA V, FANELLI F, IANNIELLO G, CIGOLARI S, PIZZA C, MARANO O, PEZZELLA G, PEDICINI T, FEBBRARO A, INCORONATO P, MANZIONE L, FERRARI E, MARZANO N, QUATTRIN S, PISCONTI S, NASTI G, GIOTTA G, COLUCCI G, SOUTHERN ITALY ONCOLOGY GROUP, CARAGLIA, Michele, Iaffaioli, Rv, Formato, R, Tortoriello, A, DEL PRETE, S, Caraglia, Michele, Pappagallo, G, Pisano, A, Gebbia, V, Fanelli, F, Ianniello, G, Cigolari, S, Pizza, C, Marano, O, Pezzella, G, Pedicini, T, Febbraro, A, Incoronato, P, Manzione, L, Ferrari, E, Marzano, N, Quattrin, S, Pisconti, S, Nasti, G, Giotta, G, Colucci, G, and SOUTHERN ITALY ONCOLOGY, Group

Published
2005

36. 'Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium'

Author

Lorusso, V., Crucitta, E., Silvestris, N., Rosati, G., Manzione, L., DE LENA, M., Palmeri, S., Gebbia, V., Mancarella, S., Sobrero, A., Pezzella, G., Comella, P., Mangiameli, A., Muci, D., ITALIAN BLADDER CANCER GROUP, LORUSSO V, CRUCITTA E, SILVESTRIS N, ROSATI G, MANZIONE L, DE LENA M, PALMERI S, GEBBIA V, MANCARELLA S, SOBRERO A, PEZZELLA G, COMELLA P, MANGIAMELI A, MUCI D, and ITALIAN BLADDER CANCER GROUP

Subjects
Paclitaxel, Bladder cancer, Gemcitabine
Abstract

The purpose of the study was to evaluate the antitumor activity and the safety of paclitaxel combined with gemcitabine and cisplatin in patients affected by advanced transitional cell carcinoma of the urothelium (TCC). Eighty-five patients affected by advanced TCC and measurable disease were randomized to receive either paclitaxel at dosage of 70 mg/m2, gemcitabine 1000 mg/m2 and cisplatin 35 mg/m2 on days 1 and 8 every 3 weeks (GCP) or gemcitabine 1000 mg/m2 on days 1, 8, 15 and cisplatin 70 mg/m2 on day 2 every 4 weeks (GC). All enrolled patients were considered evaluable for response and toxicity (intention to treat). The observed response rate was 43% for GCP and 44% for GC combination, respectively. Median time to treatment failure was 32 weeks for GCP and 26 weeks for GC and overall survival 61 vs 49 weeks, respectively (p-value not significant). Grade 3-4 neutropenia was observed in 49% of patients treated with GCP vs 35% of those treated with GC (P=0.05) and grade 3-4 thrombocytopenia was observed in 36% of GCP treated patients as compared to 21% of those treated with GC (P=0.01). Seven patients over 70 years old or with poor PS were removed from the study: 6 patients from GCP group (2 toxic deaths, 2 grade 4 myelotoxicity and 2 grade 3 asthenia) and 1 from GC group was lost to follow-up after the first cycle. The combination of paclitaxel, gemcitabine and cisplatin is effective in the treatment of TCC. However, the addition of paclitaxel to the combination of gemcitabine plus cisplatin seems to increase toxicity, therefore it seems not suitable for poor PS patients and those over 70 years old. Larger and more powered studies are needed to exactly define the role of paclitaxel in this combination.

Published
2005

37. Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.)

Author

GALETTA D, GIOTTA F, ROSATI G, GEBBIA, Vittorio, MANZIONE L, DI BISCEGLIE M, BORSELLINO N, COLUCCI G, PUCCI, Ida, GALETTA D, GIOTTA F, ROSATI G, GEBBIA V, MANZIONE L, DI BISCEGLIE M, BORSELLINO N, COLUCCI G, and Pucci, I.

Subjects
Raltitrexed, Head and neck squamous cell carcinoma, Carboplatin
Abstract

ackground: The combination of cisplatin (CDDP) and 5-Fluorouracil (5-FU) is a standard regimen for the treatment of recurrent and metastatic head and neck squamous cell carcinoma (HNSCC). This combination shows a relevant toxicity and new chemotherapy associations with a more favourable toxicity profile are awaited. Carboplatin (CB) is a platinum derivative with less toxicity than CDDP. Raltitrexed (R) is a potent and specific thymidylate synthase inhibitor with activity comparable to that of 5-FU in colorectal cancer; moreover, it showed activity as a single agent in HNSCC. Materials and Methods: Since 2001, a multicentre, phase II trial has been underway to evaluate the efficacy and toxicity of the CB+R combination in untreated patients with recurrent or metastatic HNSCC. Thirty-two patients were enrolled and included in an intent-to-treat analysis. Toxicity was graded according to NCI criteria. Patients had a histo/cytologically proven recurrent or metastatic HNSCC; patients with locally advanced disease not amenable to CDDP+5-FU treatment were also included. Patients had to be > 18 years old with ECOG PS of 0-2 and adequate bone marrow, renal and liver functions. CB (AUC 5) and R (3 mg/m 2) were administered intravenously every 3 weeks. The median age was 62 years (range 43-71), 29 M/3 F. The median PS was 1 (0-2). Twelve patients were staged III and 20 were metastatic (10 recurrent). The oral cavity/oropharynx were the primary site in 20 patients and the larynx in 10 patients. The median number of cycles delivered was 3, while globally 115 cycles were administered. The median time to progression was 4.2 months and median duration of survival was 9.8 months. Results: Seven patients achieved a partial response (22%), 10 patients showed a stable disease (31%), while 13 patients (48%) had progressive disease. Eight patients (25%) had a G 3-4 neutropenia, while G 3-4 anaemia was observed in 2 patients and thrombocytopenia in 1 patient. No extrahaematological G 3-4 toxicities were observed. A persistent G 2 hepatic toxicity led a patient to drop out from the study. Conclusion: In our phase II trial, CB in combination with R showed a moderate activity with safe administration on an outpatient basis

Published
2005

38. A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer

Author

DE PLACIDO, SABINO, DE LAURENTIIS, MICHELINO, LAURIA, ROSSELLA, PETRELLA, GIUSEPPE, LIMITE, GENNARO, COSTANZO, RAFFAELE, DE LENA M, LORUSSO V, PARADISO A, D'APRILE M, PISTILLUCCI G, FARRIS A, SAROBBA MG, PALAZZO S, MANZIONE L, ADAMO V, PALMERI S, FERRAU F, PAGLIARULO C, BIANCO AR, GOCSI COOPERATIVE G.R.O.U.P., DE PLACIDO, Sabino, DE LAURENTIIS, Michelino, DE LENA, M, Lorusso, V, Paradiso, A, D'Aprile, M, Pistillucci, G, Farris, A, Sarobba, Mg, Palazzo, S, Manzione, L, Adamo, V, Palmeri, S, Ferrau, F, Lauria, Rossella, Pagliarulo, C, Petrella, Giuseppe, Limite, Gennaro, Costanzo, Raffaele, Bianco, Ar, and GOCSI COOPERATIVE, G. R. O. U. P.

Abstract

The sequential doxorubicin --> CMF (CMF=cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF x 6 cycles (CMF); (b) doxorubicin x 4 cycles followed by CMF x 6 cycles (A --> CMF); (c) CMF x 6 cycles followed by goserelin plus tamoxifen x 2 years (CMF --> GT); and (d) doxorubicin x 4 cycles followed by CMF x 6 cycles followed by goserelin plus tamoxifen x 2 years (A --> CMF --> GT). The study used a 2 x 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A --> CMF or arms a+c vs b+d) and (2) the effect of adding GT after chemotherapy (arms a+b vs c+d). At a median follow-up of 72 months, A --> CMF as compared to CMF significantly improved disease-free survival (DFS) with a multivariate hazard ratio (HR)=0.740 (95\% confidence interval (CI): 0.556-0.986; P=0.040) and produced a nonsignificant improvement of overall survival (OS) (HR=0.764; 95\% CI: 0.489-1.193). The addition of GT after chemotherapy significantly improved DFS (HR=0.74; 95\% CI: 0.555-0.987; P=0.040), with a nonsignificant improvement of OS (HR=0.84; 95\% CI: 0.54-1.32). A --> CMF is superior to CMF. Adding GT after chemotherapy is beneficial for premenopausal node-positive patients..

Published
2005

39. Topotecan compared with no terapy and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study

Author

DE PLACIDO S, SCAMBIA G, DI VAGNO G, NAGLIERI E, LOMBARDI A. V, BIAMONTE R, MARINACCIO M, CARTENI G, MANZIONE L, FEBBRARO A, DE MATTEIS A, DANESE S, PERRONE F, LAURIA R, DE LAURENTIS M, GREGGI S, GALLO C, PIGNATA S., VALERIO, Maria Rosaria, DE PLACIDO S, SCAMBIA G, DI VAGNO G, NAGLIERI E, LOMBARDI A V, BIAMONTE R, MARINACCIO M, CARTENI G, MANZIONE L, FEBBRARO A, DE MATTEIS A, VALERIO MR, DANESE S, PERRONE F, LAURIA R, DE LAURENTIS M, GREGGI S, GALLO C, and PIGNATA S

Published
2004

40. Supportive care in patients with advanced non-small-cell lung cancer

Author

DI MAIO, Massimo, Perrone, F, Gallo, C, Iaffaioli, Rv, Manzione, L, Piantedosi, Fv, Cigolari, S, Illiano, A, Barbera, S, Robbiati, Sf, Piazza, E, Ianniello, Gp, Frontini, L, Veltri, E, Castiglione, F, Rosetti, F, De Maio, E, Maione, P, Gridelli, C, Rossi, A, Barletta, E, Barzelloni, Ml, Signoriello, G, Bilancia, D, Dinota, A, Rosati, G, Germano, D, Lamberti, A, Pontillo, V, Brancacio, L, Crispino, C, Esposito, M, Battiloro, C, Tufano, G, Cioffi, A, Guardasole, V, Angelini, V, Guidetti, G, Renda, F, Romano, F, Volpintesta, A, Sannicolò, M, Filipazzi, V, Esani, G, Gambaro, A, Ferrario, S, Tinessa, V, Caprio, Mg, Zonato, S, Cabiddu, M, Raina, A, D'Aprile, M, Pistillucci, G, Porcile, G, Ostellino, O, Vinante, O, Azzarello, G, Gebbia, V, Borsellino, N, Testa, A, Gasparini, G, Morabito, A, Gattuso, D, Romito, S, Carrozza, F, Fava, S, Calcagno, A, Grimi, E, Bertetto, O, Ciuffreda, L, Parello, G, Maiorino, L, Santoro, A, Santoro, M, Failla, G, Aiello, Ra, Bearz, A, Sorio, R, Scalone, S, Clerici, M, Bollina, R, Belloni, P, Sacco, C, Sibau, A, Adamo, V, Altavilla, G, Scimone, A, Spatafora, M, Bellia, V, Hopps, Mr, Monfardini, S, Favaretto, A, Stefani, M, Corradini, Gm, Pavia, G, Scagliotti, Giorgio Vittorio, Novello, Silvia, Selvaggi, G, Tonato, M, Darwish, S, Michetti, G, Belometti, Mo, Labianca, R, Quadri, A, De Marinis, F, Migliorino, Mr, Martelli, O, Colucci, G, Galetta, D, Giotta, F, Isa, L, Candido, P, Rossi, N, Calandriello, A, Ferraù, F, Malaponte, E, Barni, S, Cazzaniga, M, Gebbia, N, Valerio, Mr, Belli, M, Colantuoni, G, Capuano, Ma, Angiolillo, M, Sollitto, F, Ardizzoia, A, Luporini, G, Locatelli, Mc, Pari, F, Aitini, E, Pedicini, T, Febbraro, A, Zollo, C, Di Costanzo, F, Bartolucci, R, Gasperoni, S, Gaion, F, Palazzolo, G, Galligioni, E, Caffo, O, Cortesi, E, D'Auria, G, Curcio, C, Vasta, M, Bumma, C, Celano, A, Bretti, S, Nettis, G, Anselmo, A, Mattioli, R, Nisticò, C, Aschelter, A, Foa, P., DI MAIO, M, Perrone, F, Gallo, Ciro, Iaffaioli, Rv, Manzione, L, Piantedosi, Fv, Cigolari, S, Illiano, A, Barbera, S, Robbiati, Sf, Piazza, E, Ianniello, Gp, Frontini, L, Veltri, E, Castiglione, F, Rosetti, F, DE MAIO, E, Maione, P, and Gridelli, C.

Subjects
Adult, Male, concomitant drugs, Cancer Research, medicine.medical_specialty, Aging, Palliative care, Lung Neoplasms, medicine.medical_treatment, Vinorelbine, Vinblastine, Deoxycytidine, Clinical, Quality of life, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, polypharmacotherapy, medicine, Humans, Lung cancer, Survival rate, Aged, Randomized Controlled Trials as Topic, Aged, 80 and over, Chemotherapy, Performance status, business.industry, Palliative Care, Middle Aged, medicine.disease, Gemcitabine, Surgery, Survival Rate, supportive care, lung cancer, Oncology, Concomitant, Quality of Life, Antiemetics, Female, Cisplatin, business, medicine.drug
Abstract

The present study describes supportive care (SC) in patients with advanced non-small-cell lung cancer (NSCLC), evaluating whether it is affected by concomitant chemotherapy, patient's performance status (PS) and age. Data of patients enrolled in three randomised trials of first-line chemotherapy, conducted between 1996 and 2001, were pooled. The analysis was limited to the first three cycles of treatment. Supportive care data were available for 1185 out of 1312 (90%) enrolled patients. Gastrointestinal drugs (45.7%), corticosteroids (33.4%) and analgesics (23.8%) were the most frequently observed categories. The mean number of drugs per patient was 2.43; 538 patients (45.4%) assumed three or more supportive drugs. Vinorelbine does not produce substantial variations in the SC pattern, while cisplatin-based treatment requires an overall higher number of supportive drugs, with higher use of antiemetics (41 vs 27%) and antianaemics (10 vs 4%). Patients with worse PS are more exposed to corticosteroids (42 vs 30%). Elderly patients require drugs against concomitant diseases significantly more than adults (20 vs 7%) and are less frequently exposed to antiemetics (12 vs 27%). In conclusion, polypharmacotherapy is a relevant issue in patients with advanced NSCLC. Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults.

Published
2004

41. Mitoxantrone + Prednisone versus Taxotere + Prednisone nel trattamento del carcinoma prostatico ormonorefrattario (cpor ). Studio randomizzato di fase II del Gruppo Oncologico dell’Italia Meridionale (GOIM ). VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004

Author

GIOTTA F, MANZIONE L, LORUSSO V, CARUSO M, FORTUNATO S, ROMANO R. A, ROMITO S, DURINI E, BRUNETTI C, COLUCCI G., GEBBIA, Vittorio, VALERIO, Maria Rosaria, GIOTTA F, MANZIONE L, LORUSSO V, CARUSO M, FORTUNATO S, ROMANO R A, ROMITO S, GEBBIA V, VALERIO MR, DURINI E, BRUNETTI C, and COLUCCI G

Published
2004

42. Activity and toxicity of gemcitabine and gemcitabine plus vinorelbine in advanced non-small-cell lung cancer elderly patients. Phase II data from the MILES (Multicenter Italian Lung cancer in the Elderly Study) randomized trial

Author

GRIDELLI C, CIGOLARI S, MANZIONE L, IANNIELLO GP, FRONTINI L, FERRAÙ F, ROBBIATI SF, ADAMO V, GASPARINI G, NOVELLO S, PERRONE F., GALLO, Ciro, Gridelli, C, Cigolari, S, Gallo, Ciro, Manzione, L, Ianniello, Gp, Frontini, L, Ferraù, F, Robbiati, Sf, Adamo, V, Gasparini, G, Novello, S, and Perrone, F.

Published
2001

43. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial

Author

Cognetti, F, Ruggeri, Em, Felici, A, Gallucci, M, Muto, G, Pollera, Cf, Massidda, B, Rubagotti, A, Giannarelli, D, Boccardo, F, Cantiani, R, Adamo, Vincenzo, Aglietta, M, Bertetto, O, Cetto, Gl, Orlandini, P, Ferrazzi, E, Nardi, M, Manzione, L, Porcile, G, Lentini, M, Breda, E, Gamucci, T, Tummarello, D, Dogliotti, L, Tumolo, S, Motta, M, Lo Russo, V, De Grande, G, Sacco, C, Gaion, F, Lavarello, A, Nuzzo, A, Clerico, M, Aragona, C, Gernone, A, Morelli, F, Cupini, Mattioli, R, Marra, A, Antimi, M, Silingardi, V, Labianca, R, Martoni, A, Bortolussi, V, Luoni, M, Rosabian, A, Di Vito, F, Catalano, G, and Gebbia, N.

Subjects
bladder cancer adjuvant chemotherapy phase III trial
Published
2012

44. Adjuvant chemotherapy in completely resected gastric cancer: A Randomized phase III trial conducted by GOIRC

Author

Di Costanzo, F., Gasperoni, S., Manzione, L., Bisagni, G., Labianca, R., Bravi, S., Cortesi, Enrico, Carlini, P., Bracci, R., Tomao, Silverio, Messerini, L., Arcangeli, A., Torri, V., Bilancia, D., Floriani, I., Tonato, M., Italian Oncology Group For Cancer Research, Dinota, A., Strafiuso, G., Corgna, E., Porrozzi, S., Boni, C., Rondini, E., Giunta, A., Monzio Compagnoni, B., Biagioni, F., Cesari, M., Fornarini, G., Nelli, F., Carboni, M., Cognetti, F., Enzo, Mr, Piga, A., Romiti, A., Olivetti, A., Masoni, Luigi, De Stefanis, M., Dalla Mola, A., Camera, S., Recchia, F., De Filippis, S., Scipioni, L., Zironi, S., Luppi, G., Italia, M., Banducci, S., Pisani Leretti, A., Massidda, B., Ionta, M. T., Nicolosi, A., Canaletti, R., Biscottini, B., Grigniani, F., Rovei, R., Croce, E., Carroccio, R., Gilli, G., Cavalli, C., Olgiati, A., Pandolfi, U., Rossetti, R., Natalini, G., Foa, P., Oldani, S., Bruno, L., Cascinu, S., Catalano, G., Catalano, V., Lungarotti, F., Farris, A., Sarobba, M. G., Trignano, M., Muscogiuri, A., Francavilla, F., Figoli, F., Leoni, M., Papiani, G., Orselli, G., Antimi, M., Bellini, V., Cabassi, A., Contu, A., Pazzola, A., Frignano, M., Lastraioli, E., Saggese, M., Bianchini, D., Antonuzzo, L., Mela, M., and Camisa, R.

Subjects
Male, Cancer Research, medicine.medical_treatment, Leucovorin, Kaplan-Meier Estimate, Gastroenterology, Antineoplastic Combined Chemotherapy Protocols, Medicine, Stomach cancer, Adult, Aged, Biomarkers, Tumor, Chemotherapy, Adjuvant, Cisplatin, Diarrhea, Disease-Free Survival, Epirubicin, Female, Fluorouracil, Hematologic Diseases, Humans, Immunohistochemistry, Italy, Lymph Node Excision, Lymphatic Metastasis, Middle Aged, Mucositis, Neoplasm Staging, Patient Compliance, Prognosis, Proportional Hazards Models, Stomach Neoplasms, Treatment Outcome, Vomiting, Gastrectomy, Hazard ratio, Chemotherapy regimen, Oncology, medicine.drug, medicine.medical_specialty, Internal medicine, Survival analysis, Chemotherapy, business.industry, Proportional hazards model, medicine.disease, Surgery, business
Abstract

Background Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor. Methods Patients with histologically proven adenocarcinoma of the stomach of stages IB, II, IIIA and B, or IV (T4N2M0) and treated with potentially curative surgery were randomly assigned to follow-up alone or to intravenous treatment with four cycles (repeated every 21 days) of PELF (cisplatin [40 mg/m 2 , on days 1 and 5], epirubicin [30 mg/m 2 , days 1 and 5], L-leucovorin [100 mg/m 2 , days 1-4], and 5-fluorouracil [300 mg/m 2 , days 1-4] in a hospital setting. Frequencies and severity of adverse events were determined. Overall survival (OS) and disease-free survival (DFS) were compared between the treatment arms using Kaplan-Meier analysis and a Cox proportional hazards regression model. All statistical tests were two-sided. Results From January 1995 through September 2000, 258 patients were randomly assigned to chemotherapy (n = 130) or surgery alone (n = 128). Patient characteristics were well balanced between the two arms. Among those who received chemotherapy, grade 3 or 4 toxic effects including vomiting, mucositis, and diarrhea were experienced by 21.1%, 8.4%, and 11.8% of patients, respectively. Leucopenia, anemia, and thrombocytopenia of grade 3 or 4 were experienced by 20.3%, 3.3%, and 4.2% of patients, respectively. After a median follow-up of 72.8 months, 128 patients (49.6%) experienced recurrence and 139 (53.9%) deaths were observed, one toxicity-related. Relative to treatment with surgery alone, adjuvant chemotherapy did not increase disease-free survival (hazard ratio [HR] of recurrence = 0.92; 95% confidence interval [Cl] = 0.66 to 1.27) or overall survival (HR of death = 0.90; 95% Cl = 0.64 to 1.26). Conclusions Our results failed to provide proof of an effect of adjuvant chemotherapy with PELF on overall survival or disease-free survival. The estimated effect of chemotherapy (10% reduction in the hazard of death or relapse) is modest and consistent with the results of meta-analyses of adjuvant chemotherapy without platinum agents.

Published
2008

45. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study

Author

Pignata, S., Ferrandina, G., Scarfone, G., Scollo, P., Odicino, F., Selvaggi, L., Katsaros, D., Frigerio, L., Mereu, L., Ghezzi, F., Manzione, L., Lauria, R., Breda, E., Marforio, G., Ballardini, M., Vernaglia Lombardi, A., Sorio, R., Tumolo, S., Costa, B., Magni, G., Perrone, F., and Favalli, G.

Subjects
Ovarian Neoplasms, Salvage Therapy, Time Factors, Drug Resistance, Antineoplastic Agents, Platinum Compounds, Middle Aged, Survival Analysis, Aged, Cohort Studies, Drug Resistance, Neoplasm, Female, Humans, Recurrence, Retrospective Studies, Treatment Outcome, Ovarian cancer, Chemotherapy, Neoplasm
Abstract

It has been proposed that extending the platinum-free interval with intervening non-platinum therapy increases the efficacy of a later re-treatment with platinum in platinum-sensitive recurrent ovarian cancer. This hypothesis is based on data from small series and although it has not been validated prospectively, this strategy has entered general practice in Italy in the last years. The SOCRATES study retrospectively assessed the pattern of care of a cohort of patients with recurrent platinum-sensitive ovarian cancer observed in the years 2000-2002 in 37 Italian centres. Data were collected between April and September 2005.Patients with recurrent ovarian cancer with a platinum-free interval6 months were eligible. 493 patient files were collected and 428 were eligible and analyzed.The interval from the end of the 1st line to relapse was 6-12 months in 164 patients (39.5%) and12 months in 251 cases (60.5%). Patients received a 2nd (100%), 3rd (80.1%), 4th (50.2%), 5th (28.3%), and 6th (11.9%) line of chemotherapy. At 2nd line 282 (65.9%) received platinum (group A), while 146 (34.1%) received non-platinum chemotherapy (group B). In the latter group, 67 patients received platinum at later progression (group B1), while 79 never received platinum (group B2). Median time to platinum re-treatment was 20 and 23.1 months in patients of groups A and B1, respectively. The response rate to the first platinum received was 74.4 and 57.4% in groups A and B1, respectively (p = 0.02). Group B2 was characterized by the worst response rate and survival. At multivariate analysis time of first platinum re-treatment (2nd line vs. later; p = 0.0132; OR = 2.34) and age (p = 0.0029; OR = 2.41) was independently associated with a higher possibility of response to platinum.With the limits of a retrospective study, our data question the hypothesis that extending the platinum-free interval with an intervening non-platinum therapy in patients with recurrent platinum-sensitive ovarian cancer improves the response rate of a further platinum re-treatment.

Published
2007

47. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancerreceiving chemotherapy: a prognostic analysis of the multicenter Italian lungcancer in the elderly study

Author

Maione, P, Perrone, F, Gallo, C, Manzione, L, Piantedosi, F, Barbera, S, Cigolari, S, Rosetti, F, Piazza, E, Robbiati, Sf, Bertetto, O, Novello, S, Migliorino, Mr, Favaretto, A, Spatafora, M, Ferrau, F, Frontini, L, Bearz, A, Repetto, L, Gridelli, C, Barletta, E, Barzelloni, Ml, Iaffaioli, Rv, DE MAIO, E, DI MAIO, M, DE FEO, G, Sigoriello, G, Chiodini, P, Cioffi, A, Guardasole, V, Angelini, V, Rossi, A, Bilancia, D, Germano, D, Lamberti, A, Pontillo, V, Brancaccio, L, Renda, F, Romano, F, Esani, G, Gambaro, A, Vinante, O, Azzarello, G, Clerici, M, Bollina, R, Belloni, P, Sannicolo, M, Ciuffreda, L, Parello, G, Cabiddu, M, Sacco, C, Sibau, A, Porcile, G, Castiglione, F, Ostellino, O, Monfardini, S, Stefani, M, Scagliotti, G, Selvaggi, G, DE MARINIS, F, Martelli, O, Gasparini, G, Morabito, A, Gattuso, D, Colucci, G, Galetta, D, Giotta, F, Gebbia, V, Borsellino, N, Testa, A, Malaponte, E, Capuano, Ma, Angiolillo, M, Sollitto, F, Tirelli, U, Spazzapan, S, Adamo, Vincenzo, Altavilla, Giuseppe, Scimone, A, Hopps, Mr, Tartamella, F, Ianniello, Gp, Tinessa, V, Failla, G, Bordonaro, R, Gebbia, N, Valerio, Mr, D'Aprile, M, Veltri, E, Tonato, M, Darwish, S, Romito, S, Carrozza, F, Barni, S, Ardizzoia, A, Corradini, Gm, Pavia, G, Belli, M, Colantuoni, G, Galligioni, E, Caffo, O, Labianca, R, Quadri, A, Cortesi, E, D'Auria, G, Fava, S, Calcagno, A, Luporini, G, Locatelli, Mc, DI COSTANZO, F, Gasperoni, S, Isa, L, Candido, P, Gaion, F, Palazzolo, G, Nettis, G, Annamaria, A, Rinaldi, M, Lopez, M, Felletti, R, DI NEGRO GB, Rossi, N, Calandriello, A, Maiorino, L, Mattioli, R, Celano, A, Schiavon, S, Illiano, A, Raucci, Ca, Caruso, M, Foa, P, Tonini, G, Curcio, C, and Cazzaniga, M.

Published
2005

50. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide (vol 22, pg 725, 2004)

Author

Roila, F, Ballatori, E, Bosnjak, S, Tonato, M, Basurto, C, Betti, M, Bonciarelli, V, Cianchetti, M, Susnjar, S, Neskovic-Konstantinovic, Z, Stamotovic, L, Marinkovic, Z, Rosati, G, Manzione, L, Rossi, A, Germano, D, Romano, R, Nuzzo, A, Laudadio, L, D'Ostilio, N, Forciniti, S, Buzzi, F, Bartolucci, R, Fumi, G, Catanzani, S, Gamucci, T, Ferraresi, V, Trombetta, G, Vaccaro, A, Contu, A, Olmeo, N, Baldino, G, Campora, E, Venturino, A, Addamo, G, Silva, Rr, Giuliodori, L, Bisonni, R, Dazzi, C, Cariello, A, Zumaglini, F, Tonini, G, Santini, D, Vincenzi, B, Fava, S, Grimi, E, Luoni, M, Picece, V, Nicodemo, M, Recaldin, E, Donati, D, Margutti, G, Cortesi, E, D'Auria, G, Lalli, A, Di Giandomenico, F, Massidda, B, Ionta, Mt, Alessandroni, P, Baldelli, Am, Pinaglia, D, Sassi, M, Sabbatini, R, Maur, M, di Castello, C, Porrozzi, S, Bravi, S, Eugenio, S, Antimi, M, Gridelli, C, and Verusio, C

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results